stockrow
Friday 6 November 2026
Export XENE’s income statement to Excel — free account
Xenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
39.00
1.32
+3.50%
Follow XENE
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 3 | 3 | — | — | — | 1 | 2 |
P/E ratio |
0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
P/S ratio |
209.76 | — | — | 171.27 | 73.92 | 16.52 | 47.84 | — | 166.55 | 67.45 |
Altman Z-Score |
37.76 | — | — | 43.34 | 37.06 | 16.50 | 1.21 | — | (3.53) | 16.92 |
Altman Z″-Score (non-manufacturers) |
6.89 | — | — | 24.99 | 29.56 | 9.97 | (1.22) | — | (7.50) | 15.38 |
P/FCF ratio |
0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | 1.12 | (1.63) | 1.94 | — | — | 5.34 | (0.58) |
P/Operating CF |
(43.59) | — | — | (68.92) | (65.81) | (40.51) | 17.19 | — | (7.57) | (26.04) |
P/B ratio |
6.11 | — | — | 3.13 | 2.51 | 3.25 | 4.04 | — | 1.44 | 1.90 |
Price to Tangible BV |
6.11 | — | — | 3.13 | 2.51 | 3.25 | 4.04 | — | 1.44 | 1.90 |
EV/Sales |
178.92 | — | — | 128.33 | 45.44 | 11.84 | 30.14 | — | 48.02 | 31.88 |
EV/EBITDA |
0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
EV/Operating CF |
(10.85) | — | — | (17.17) | (12.05) | (7.91) | (45.45) | — | (0.52) | (2.94) |
EV/FCF |
(10.82) | — | — | (16.68) | (11.71) | (7.50) | (35.98) | — | (0.51) | (2.90) |
Quick Ratio |
13.17 | 17.66 | 23.43 | 26.12 | 38.72 | 12.10 | 3.28 | 29.00 | 10.80 | 17.94 |
Current Ratio |
13.42 | 17.85 | 23.65 | 26.44 | 39.03 | 12.30 | 3.34 | 29.46 | 10.98 | 18.31 |
Net Debt/EBITDA |
1.48 | 2.27 | 3.01 | 4.64 | 7.07 | 5.81 | 3.01 | 2.81 | 1.16 | 2.68 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.52% | 12.26% | 14.75% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.15 | 0.19 | 0.00 |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.01 | 0.05 | 0.19 | 0.05 | 0.00 | 0.01 | 0.03 |
Operating CF/Net income |
0.81 | 0.77 | 0.83 | 0.79 | 0.90 | 1.72 | 0.12 | 1.10 | 0.94 | 0.85 |
Capex/Depreciation |
(0.31) | (1.20) | (2.73) | (1.78) | (2.26) | (3.07) | (1.30) | (0.58) | (0.48) | (0.32) |
Interest Coverage |
— | — | — | (14.82) | (169.51) | (64.67) | (29.86) | (27.29) | (68.29) | (49.24) |
| (51.76%) | (27.85%) | (22.12%) | (19.77%) | (21.84%) | (22.60%) | (44.52%) | (48.09%) | (61.51%) | (36.81%) | |
| (48.34%) | (26.58%) | (21.22%) | (18.84%) | (20.25%) | (16.63%) | (29.64%) | (37.52%) | (54.05%) | (34.99%) | |
ROIC |
(709.28%) | (136.38%) | (46.16%) | (62.37%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(65.57%) | (38.42%) | (29.07%) | (21.39%) | (14.04%) | (16.42%) | (38.81%) | (26.75%) | (73.44%) | (36.22%) |
Average Days of Receivables |
66.72 | 0.00 | 0.00 | 38.15 | 54.74 | 20.67 | 43.45 | 0.00 | 514.05 | 40.49 |
Research and Development Expense of Revenue |
4,012.51% | 0.00% | 0.00% | 1,121.13% | 409.30% | 157.07% | 568.82% | 0.00% | 8,222.83% | 1,099.72% |
Selling, General and Administrative Expense of Revenue |
1,061.76% | 0.00% | 0.00% | 347.78% | 119.15% | 40.24% | 158.19% | 0.00% | 2,351.45% | 376.71% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
716.09% | 0.00% | 0.00% | 215.98% | 54.33% | 17.65% | 42.82% | 0.00% | 718.97% | 119.86% |
Graham Net Nets |
0.14 | — | — | 0.25 | 0.39 | 0.31 | 0.26 | — | 0.67 | 0.51 |
Graham Number |
0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Earnings Yield |
(9.73%) | — | — | (5.48%) | (5.95%) | (5.30%) | (11.75%) | — | (59.38%) | (18.85%) |
Free Cash Flow Yield |
(7.88%) | — | — | (4.49%) | (5.25%) | (9.55%) | (1.75%) | — | (56.07%) | (16.32%) |
Revenue per Share |
0.09 | 0.00 | 0.00 | 0.16 | 0.42 | 0.93 | 0.26 | 0.00 | 0.02 | 0.12 |
Operating CF per Share |
(3.52) | (2.33) | (2.26) | (1.63) | (1.59) | (1.39) | (0.18) | (1.79) | (1.60) | (1.26) |
Capex per Share |
(0.01) | (0.04) | (0.08) | (0.05) | (0.05) | (0.08) | (0.05) | (0.03) | (0.02) | (0.02) |
Free Cash Flow per Share |
(3.53) | (2.37) | (2.34) | (1.67) | (1.64) | (1.47) | (0.23) | (1.81) | (1.61) | (1.28) |
Cash per Share |
6.93 | 8.05 | 9.54 | 9.78 | 12.65 | 5.12 | 5.45 | 6.14 | 2.43 | 4.14 |
Shareholders Equity per Share |
7.34 | 9.69 | 13.87 | 11.92 | 12.61 | 4.96 | 3.55 | 5.32 | 2.00 | 4.12 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.34 | 9.69 | 13.87 | 11.92 | 12.61 | 4.96 | 3.55 | 5.32 | 2.00 | 4.12 |
Free Cash Flow |
(279.92) | (184.46) | (156.73) | (101.32) | (71.55) | (50.76) | (5.95) | (35.23) | (29.04) | (19.85) |
Working Capital |
518.86 | 599.67 | 617.69 | 577.60 | 544.70 | 167.00 | 101.49 | 117.21 | 40.74 | 62.09 |
Capital Expenditures |
(0.80) | (3.07) | (5.62) | (2.89) | (2.05) | (2.64) | (1.24) | (0.51) | (0.31) | (0.28) |
Net Current Asset Value |
509.25 | 592.03 | 608.09 | 567.65 | 537.05 | 163.95 | 89.15 | 102.20 | 34.63 | 62.09 |
EV/EBIT |
0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Capex to Sales |
0.11 | 0.00 | 0.00 | 0.31 | 0.11 | 0.08 | 0.18 | 0.00 | 1.01 | 0.15 |
Price to Operating Income |
0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.29 | 0.25 | 0.21 | 0.25 | 0.20 | 0.24 | 0.57 | 0.88 | 0.62 | 0.62 |
Cash ROIC |
(24.76%) | (13.35%) | (10.01%) | (7.71%) | (6.49%) | (14.57%) | (2.39%) | (14.83%) | (33.61%) | (15.50%) |
Accounts Receivable Turnover |
5.28 | 0.00 | 0.00 | 5.03 | 8.04 | 24.41 | 14.17 | 0.00 | 0.97 | 7.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | — | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | — | 0.00 | — | — |
Average Receivables |
1.42 | 1.17 | 0.93 | 1.88 | 2.29 | 1.32 | 0.48 | 0.29 | 0.32 | 0.26 |
Average Payables |
37.24 | 30.10 | 24.09 | 17.97 | 12.30 | 9.85 | 6.47 | 3.75 | 3.48 | 3.11 |
Average Assets |
715.65 | 881.47 | 859.47 | 663.08 | 380.60 | 168.44 | 135.06 | 84.27 | 56.80 | 65.72 |
Average Common Equity |
668.33 | 841.41 | 824.71 | 631.90 | 352.96 | 123.93 | 89.90 | 65.75 | 49.92 | 62.47 |
Columns are period end dates